Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models.
Irene Lara-SáezÁngeles MencíaEnrique RecueroYinghao LiMarta GarcíaMarta OteoMarta I GallegoAna Belén EnguitaDiana de Prado-VerdúnSigen AWenxin WangRamon Garcia-EscuderoRodolfo MurillasMirentxu SantosPublished in: Proceedings of the National Academy of Sciences of the United States of America (2024)
Functional analysis in mouse models is necessary to establish the involvement of a set of genetic variations in tumor development. A modeling platform to facilitate and cost-effectively analyze the role of multiple genes in carcinogenesis would be valuable. Here, we present an innovative strategy for lung mutagenesis using CRISPR/Cas9 ribonucleoproteins delivered via cationic polymers. This approach allows the simultaneous inactivation of multiple genes. We validate the effectiveness of this system by targeting a group of tumor suppressor genes, specifically Rb1 , Rbl1 , Pten , and Trp53 , which were chosen for their potential to cause lung tumors, namely small cell lung carcinoma (SCLC). Tumors with histologic and transcriptomic features of human SCLC emerged after intratracheal administration of CRISPR/polymer nanoparticles. These tumors carried loss-of-function mutations in all four tumor suppressor genes at the targeted positions. These findings were reproduced in two different pure genetic backgrounds. We provide a proof of principle for simplified modeling of lung tumorigenesis to facilitate functional testing of potential cancer-related genes.
Keyphrases
- crispr cas
- genome wide
- genome editing
- dna methylation
- bioinformatics analysis
- genome wide identification
- single cell
- endothelial cells
- copy number
- randomized controlled trial
- mouse model
- cell proliferation
- genome wide analysis
- high throughput
- cell therapy
- squamous cell carcinoma
- papillary thyroid
- drug delivery
- signaling pathway
- cancer therapy
- risk assessment
- squamous cell
- pi k akt
- childhood cancer